1-18 of 18
Sharon Jackson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Using Peripheral Blood (PB) Measurable Residual Disease (MRD) Levels to Predict <0.01% Bone Marrow Disease (BM uMRD4): Identification of Effective PB Targets for CLL Treatment Cessation in the Ibrutinib+Venetoclax Arm of the FLAIR Trial

Andy Rawstron, Nichola Webster, Surita Dalal, Ruth M de Tute, Sue Bell, David Allan Cairns, Sean Girvan, Natasha Greatorex, Anna Hockaday, Sharon Jackson, David Phillips, David Stones, David Allsup, Adrian John Clifton Bloor, Anita Sarma, Abraham Mullasseril Varghese, Talha Munir, Peter Hillmen
Journal: Blood
Blood (2023) 142 (Supplement 1): 632.
https://doi.org/10.1182/blood-2023-187943
Published: 2023
Journal Articles

RADAR Trial: MRD Response Adapted Trial for Newly Diagnosed Transplant Eligible Myeloma Patients

Karthik Ramasamy, David Allan Cairns, Kara-Louise Royle, Robert Cicero, Catherine Olivier, Lorna Barnard, Sharon Jackson, Doina Levinte, Gordon Cook, Alan Chant, David Meads, Bryony Dawkins, Michael A. Chapman, Guy Pratt, Rakesh Popat, Graham Jackson, Ceri Bygrave, Andrew Chantry, Martin F. Kaiser, Jonathan Sive, Christopher Parrish, Dean Smith, Matthew W. Jenner, Mark Drayson, Roger Owen, Ruth M de Tute, Dipal Mehta, Kwee Yong
Journal: Blood
Blood (2023) 142 (Supplement 1): 3390.
https://doi.org/10.1182/blood-2023-188844
Published: 2023
Journal Articles

Health-Related Quality of Life (HRQoL) in Fit, Unfit and Frail Patients Enrolled in Fitness (UK-MRA Myeloma XIV): A Cross Sectional Study

Orla McCourt, David Allan Cairns, Sally Moore, Christopher Parrish, Charlotte Pawlyn, Frances Seymour, Ethan R Senior, Kara-Louise Royle, Jennifer Bird, Stella J. Bowcock, Alan Chant, Mark Drayson, Hayley Gardner, Matthew W. Jenner, John R Jones, Martin F. Kaiser, Bhuvan Kishore, Roger Owen, Neil Rabin, Ruth M de Tute, Bryony Dawkins, David Meads, Sharon Gillson, Sharon Jackson, Catherine Olivier, Graham Jackson, Gordon Cook
Journal: Blood
Blood (2023) 142 (Supplement 1): 3368.
https://doi.org/10.1182/blood-2023-187202
Published: 2023
Journal Articles

Ibrutinib and Rituximab Versus Fludarabine, Cyclophosphamide, and Rituximab for Patients in NCRI FLAIR Study with Previously Untreated CLL: Assessment of Mutational Landscape of Patients at Baseline and Prognostic Impact

Surita Dalal, Anita Sarma, Jane Shingles, Paul Glover, Helen Warren, Thomas Grand, Nichola Webster, Andy Rawstron, Darren Newton, Sue Bell, David Allan Cairns, Sean Girvan, Natasha Greatorex, Anna Hockaday, Sharon Jackson, David Phillips, David Stones, David Allsup, Adrian John Clifton Bloor, Abraham Mullasseril Varghese, Talha Munir, Peter Hillmen
Journal: Blood
Blood (2023) 142 (Supplement 1): 4637.
https://doi.org/10.1182/blood-2023-180527
Published: 2023
Journal Articles

Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR Study

Peter Hillmen, David Allan Cairns, Adrian John Clifton Bloor, David Allsup, Kate Cwynarski, Andrew Pettitt, Shankaranarayana Paneesha, Christopher P. Fox, Toby A. Eyre, Francesco Forconi, Nagah Elmusharaf, Ben Kennedy, John G. Gribben, Nicholas Pemberton, Oonagh Sheehy, Gavin Preston, Anna Schuh, Dena Howard, Anna Hockaday, Sharon Jackson, Natasha Greatorex, Sean Girvan, Sue Bell, Julia Brown, Nichola Webster, Surita Dalal, Ruth M de Tute, Andrew Rawstron, Piers EM Patten, Talha Munir
Journal: Blood
Blood (2023) 142 (Supplement 1): 631.
https://doi.org/10.1182/blood-2023-178298
Published: 2023
Journal Articles

Health-Related Quality of Life (HRQoL) in Patients with Genetic Standard and High-Risk Disease at Trial Entry: A Cross-Sectional Analysis of RADAR (UK-MRA Myeloma XV)

Catherine SY Lecat, Alan Chant, Orla McCourt, David Meads, Robert Cicero, Kara-Louise Royle, Ceri Bygrave, Andrew Chantry, Michael A. Chapman, Gordon Cook, Bryony Dawkins, Mark Drayson, Graham Jackson, Matthew W. Jenner, Martin F. Kaiser, Dipal Mehta, Roger Owen, Rakesh Popat, Christopher Parrish, Guy Pratt, Jonathan Sive, Dean Smith, Ruth M de Tute, Lorna Barnard, Sharon Jackson, Doina Levinte, Catherine Olivier, Karthik Ramasamy, Kwee Yong, David Allan Cairns
Journal: Blood
Blood (2023) 142 (Supplement 1): 4710.
https://doi.org/10.1182/blood-2023-187453
Published: 2023
Journal Articles

Molecular Analysis at Relapse of Patients Treated on the Ibrutinib and Rituximab Arm of the National Multi-Centre Phase III FLAIR Study in Previously Untreated CLL Patients

Anita Sarma, Charlotte Evans, Surita Dalal, Nichola Webster, Andy Rawstron, Jane Shingles, Darren Newton, David Allan Cairns, Paul Glover, Thomas Grand, Helen Warren, Sue Bell, Sean Girvan, Natasha Greatorex, Anna Hockaday, Sharon Jackson, David Phillips, David Stones, David Allsup, Adrian John Clifton Bloor, Abraham Mullasseril Varghese, Talha Munir, Peter Hillmen
Journal: Blood
Blood (2023) 142 (Supplement 1): 4636.
https://doi.org/10.1182/blood-2023-188597
Published: 2023
Journal Articles

High Success Rates Utilizing Local Standard of Care Cytogenetic Testing for Risk Stratified Frontline Therapy for Newly Diagnosed Multiple Myeloma: Experience from the Ukmra RADAR Study

Dipal Mehta, Laura Chiecchio, Martin F. Kaiser, Sarah Gooding, Kara-Louise Royle, Doina Levinte, Catherine Olivier, David Allan Cairns, Lorna Barnard, Sharon Jackson, Robert Cicero, Gordon Cook, Michael A. Chapman, Alan Chant, David Meads, Bryony Dawkins, Guy Pratt, Rakesh Popat, Graham Jackson, Ceri Bygrave, Andrew Chantry, Jonathan Sive, Christopher Parrish, Dean Smith, Mark Drayson, Roger Owen, Ruth M de Tute, Karthik Ramasamy, Kwee Yong, Matthew W. Jenner
Journal: Blood
Blood (2023) 142 (Supplement 1): 6715.
https://doi.org/10.1182/blood-2023-188697
Published: 2023
Journal Articles

The clinical picture of ERCC6L2 disease: from bone marrow failure to acute leukemia

Clinical Trials & Observations
Marja Hakkarainen, Ilse Kaaja, Suvi P. M. Douglas, Tom Vulliamy, Inderjeet Dokal, Jean Soulier, Lise Larcher, Régis Peffault de Latour, Thierry Leblanc, Flore Sicre de Fontbrune, Timo Siitonen, Olli Lohi, Eva Hellström-Lindberg, Gisela Barbany, Bianca Tesi, Akiko Shimamura, Fabian Beier, Sharon Jackson, Amir Asher Kuperman, Tzipora Falik Zaccai, Hannah Tamary, Cristina Mecucci, Ilaria Capolsini, Kirsi Jahnukainen, Urpu Salmenniemi, Riitta Niinimäki, Teppo Varilo, Outi Kilpivaara, Ulla Wartiovaara-Kautto
Journal: Blood
Blood (2023) 141 (23): 2853–2866.
https://doi.org/10.1182/blood.2022019425
Published: 2023
Includes: Supplemental data
Journal Articles

Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study

Talha Munir, Alexandra Pitchford, Adrian Bloor, Andrew Pettitt, Piers E.M. Patten, Francesco Forconi, Anna Schuh, Christopher P Fox, Simona Gatto, Ben Kennedy, John Gribben, Nicholas Pemberton, Oonagh Sheehy, Gavin Preston, Dena Howard, Anna Hockaday, David Cairns, Sharon Jackson, Natasha Greatorex, Nichola McWhirter, Jane Shingles, Kate Cwynarski, Shankara Paneesha, David Allsup, Andrew Rawstron, Peter Hillmen
Journal: Blood
Blood (2022) 140 (Supplement 1): 231–233.
https://doi.org/10.1182/blood-2022-170463
Published: 2022
Journal Articles

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

Clinical Trials & Observations
Constantine S. Tam, John N. Allan, Tanya Siddiqi, Thomas J. Kipps, Ryan Jacobs, Stephen Opat, Paul M. Barr, Alessandra Tedeschi, Livio Trentin, Rajat Bannerji, Sharon Jackson, Bryone J. Kuss, Carol Moreno, Edith Szafer-Glusman, Kristin Russell, Cathy Zhou, Joi Ninomoto, James P. Dean, William G. Wierda, Paolo Ghia
Journal: Blood
Blood (2022) 139 (22): 3278–3289.
https://doi.org/10.1182/blood.2021014488
Published: 2022
Includes: Supplemental data
Journal Articles

Sudden or Cardiac Deaths on Ibrutinib-Based Therapy Were Associated with a Prior History of Hypertension or Cardiac Disease and the Use of ACE-Inhibitors at Study Entry: Analysis from the Phase III NCRI FLAIR Trial

Talha Munir, Alexandra Pitchford, Adrian Bloor, Angus Broom, Moya Young, Ben Kennedy, Renata Walewska, Michelle Furtado, Gavin Preston, Jeffrey R. Neilson, Nicholas Pemberton, Gamal Sidra, Nicholas Morley, Kate Cwynarski, Anna Schuh, Francesco Forconi, Simona Gatto, Shankara Paneesha, Christopher P. Fox, Dena Howard, Anna Hockaday, David Cairns, Sharon Jackson, Natasha Greatorex, Piers EM Patten, David Allsup, Peter Hillmen
Journal: Blood
Blood (2021) 138 (Supplement 1): 2636.
https://doi.org/10.1182/blood-2021-152167
Published: 2021
Journal Articles

Multinational Study on the Clinical and Genetic Features of the ERCC6L2-Disease

Marja Hakkarainen, Suvi P. M. Douglas, Tom Vulliamy, Inderjeet Dokal, Jean Soulier, Lise Larcher, Riitta Niinimäki, Timo Siitonen, Eva Hellstrom Lindberg, Gisela Barbany, Bianca Tesi, Amir Asher Kuperman, Hannah Tamary, Sharon Jackson, Outi Kilpivaara, Ulla Wartiovaara-Kautto
Journal: Blood
Blood (2021) 138 (Supplement 1): 864.
https://doi.org/10.1182/blood-2021-145039
Published: 2021
Journal Articles

Ibrutinib Plus Rituximab Is Superior to FCR in Previously Untreated CLL: Results of the Phase III NCRI FLAIR Trial

Peter Hillmen, Alexandra Pitchford, Adrian Bloor, Angus Broom, Moya Young, Ben Kennedy, Renata Walewska, Michelle Furtado, Gavin Preston, Jeffrey R. Neilson, Nicholas Pemberton, Gamal Sidra, Nicholas Morley, Kate Cwynarski, Anna Schuh, Francesco Forconi, Nagah Elmusharaf, Shankara Paneesha, Christopher P. Fox, Dena Howard, Anna Hockaday, David Cairns, Sharon Jackson, Natasha Greatorex, Piers EM Patten, David Allsup, Talha Munir
Journal: Blood
Blood (2021) 138 (Supplement 1): 642.
https://doi.org/10.1182/blood-2021-152319
Published: 2021
Journal Articles

Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1-Year Disease-Free Survival (DFS) Results From the MRD Cohort of the Phase 2 CAPTIVATE Study

William G. Wierda, MD PhD, Constantine S. Tam, MD, John N. Allan, MD, Tanya Siddiqi, MD, Thomas J. Kipps, MD PhD, Stephen Opat, FRACP, FRCPA, MBBS, Alessandra Tedeschi, MD, Xavier C. Badoux, MBBS, FRACP, FRCPA, Bryone J. Kuss, MBBS, PhD FRACP, FRCPA, Sharon Jackson, MD, Carol Moreno, MD PhD, Ryan Jacobs, MD, John M. Pagel, MD PhD, Ian W. Flinn, MD PhD, Cathy Zhou, MS, Edith Szafer-Glusman, PhD, Joi Ninomoto, PharmD, James P. Dean, MD PhD, Danelle F. James, MD MAS, Paolo Ghia, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 16–17.
https://doi.org/10.1182/blood-2020-134446
Published: 2020
Journal Articles

Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537)

Philippe Moreau, Tamás Masszi, MD, Norbert Grzasko, MD PhD, Nizar J Bahlis, MD, Markus Hansson, Ludek Pour, MD, Irwindeep Sandhu, MD, Peter Ganly, BMBCh, PhD, Bartrum W Baker, MBChB, FRACP, FRCPA, Sharon Jackson, MBChB, FRACP, FRCPA, Anne-Marie Stoppa, MD, David R Simpson, MBChB, FRACP, FRCPA, Peter Gimsing, MD DMSci, Antonio Palumbo, Laurent Garderet, MD, Michele Cavo, Shaji K. Kumar, MD, Cyrille Touzeau, MD, Francis Buadi, MD, Jacob P. Laubach, MD, Jianchang Lin, PhD, Deborah Berg, RN, MSN, Alessandra DiBacco, PhD, Ai-Min Hui, MD PhD, Paul G. Richardson, MD
Journal: Blood
Blood (2015) 126 (23): 727.
https://doi.org/10.1182/blood.V126.23.727.727
Published: 2015
Journal Articles

Antibodies Targeting Subunit 1 of the N -Methyl-D-Aspartate Receptor May Contribute to Immune Mediated Thrombocytopenia.

Maggie L. Kalev-Zylinska, MD, PhD, FRCPA, Hilary A. Blacklock, Gordon Royle, Ross Henderson, Peter Flanagan, Sharon Jackson, Isuru Dilshan, Wymond Symes, Kathryn Goldstone, Peter Browett, Matthew J. During
Journal: Blood
Blood (2007) 110 (11): 2110.
https://doi.org/10.1182/blood.V110.11.2110.2110
Published: 2007
Journal Articles

Fixed-Dose, Weight-Adjusted, Unfractionated Heparin (UFH) Given Subcutaneously (sc) without Laboratory Monitoring for Acute Treatment of Venous Thromboembolism (VTE): Randomized Comparison with Low-Molecular-Weight-Heparin (LMWH).

Clive Kearon, MD, Jeffrey J. Ginsberg, MD, Jim Julian, James Douketis, MD, Susan Solymoss, MD, Paul Ockelford, MD, Sharon Jackson, MD, Graham Turpie, MD, Donna McCarty, Betsy MacKinnon, Jack Hirsh, MD, Michael Gent, (for the FIDO Investigators)
Journal: Blood
Blood (2004) 104 (11): 707.
https://doi.org/10.1182/blood.V104.11.707.707
Published: 2004